Michael S. Cookson, MD, MMHC, Author at Grand Rounds in Urology

Michael S. Cookson, MD, MMHC

University of Oklahoma College of Medicine

Oklahoma City, Oklahoma

Michael S. Cookson, MD, MMHC, is Professor and Chairman of the Department of Urology and holds the Donald D. Albers Endowed Chair in Urology at the University of Oklahoma Health Sciences Center in Oklahoma City. He has authored some 240 peer-reviewed journal publications as well as more than 30 chapters of various textbooks, and he is nationally recognized for his outstanding contributions to urologic oncology. Dr. Cookson completed his Urology Residency at the University of Texas, San Antonio, and completed his Urologic Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York. From 1998 to 2013, he served as the Vice Chairman of Urologic Surgery and Director of the Urologic Oncology Fellowship Program at Vanderbilt University. Dr. Cookson has devoted much of his academic career to the management of patients with urologic cancers, with a strong emphasis on clinical guidelines, education, and evidenced-based medicine. He was a member of the AUA/ABU Examination Committee for 10 years, serving as Oncology Consultant and Pathology Editor. He also serves on the ABU Oral Examination Committee. He is a Co-Founder of the Oncology Knowledge Assessment Test (OKAT), an SUO-mandated examination. He also served as Chair for the OKAT for 5 years. In 2011, he received the President’s Distinguished Service Award from the SUO for educational contributions. He received the 2018 AUA Presidential Citation for Outstanding Service for his role in the development of the OKAT and as Chair of the Castration-Resistant Prostate Cancer Guidelines Committee at the AUA 2018 Annual Meeting. Dr. Cookson has previously served as a member of the AUA Guidelines on Localized Prostate Cancer Committee. Dr. Cookson is currently serving out the 2019-2020 term as the SUO President.

Disclosures:

Talks by Michael S. Cookson, MD, MMHC

A Review of AUA / SUO / ASTRO Guidelines for MIBC

Posted by Michael S. Cookson, MD, MMHC | Jun 2021

Michael S. Cookson, MD, MMHC, Professor and Chairman of the Department of Urology at the University of Oklahoma Health Sciences Center, summarizes the updated AUA/SUO/ASTRO guideline for the treatment of muscle-invasive bladder cancer (MIBC), a particularly deadly and difficult-to-treat disease. He explains the purpose and methodology of the guideline, summarizes its contents, and makes a note of recent and ongoing research in the areas of chemotherapy, extended pelvic lymphadenectomy, and bladder preservation that may change the guidelines in the future.

Changing Landscape of mHSPC: New Approaches to an Old Problem

Posted by Michael S. Cookson, MD, MMHC | Jun 2020

Michael S. Cookson, MD, MMHC, Professor and Chairman of the Department of Urology at the University of Oklahoma Health Sciences Center in Oklahoma City, gives an overview of the changing landscape of metastatic hormone-sensitive prostate cancer (mHSPC). He reviews the different treatment strategies that have undergone testing over the last eight decades, noting that although treatment options have progressed, there is still work to be done to continue improving results. He presents the findings of key studies that look to improve survival through the use of more potent androgen-targeting techniques, among other cutting edge treatments. These new treatments show promising results in lowering risk of spread and death, bolstering Dr. Cookson’s key point: that the landscape is rapidly changing, and urologists need to adapt quickly.

New Approaches to Metastatic Hormone Sensitive Prostate Cancer

Posted by Michael S. Cookson, MD, MMHC | Mar 2020

Michael S. Cookson, MD, MMHC, Professor of Urology at the University of Oklahoma, reviews the current treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC). He goes on to discuss several aspects of the disease, including classifying patients into low or high risk, how to incorporate androgen axis inhibitors with ADT in managing newly diagnosed patients, and how to identify patients who may be candidates for chemotherapy plus ADT in patients with mHSPC.

A Urologist’s Perspective on Germline Testing

Posted by Michael S. Cookson, MD, MMHC | Oct 2019

Michael S. Cookson, MD, MMHC, stresses that, in the current landscape of increased public awareness and commercial availability of germline testing, urologists must stay informed in order to utilize genetic information for the risk assessment, prevention, and prognosis of prostate cancer, as well as guide treatment selections. Dr. Cookson then reviews the existing guidelines regarding the role of germline testing in managing prostate cancer, including recommendations from the Society of Urologic Oncology, National Comprehensive Cancer Network, and the Philadelphia Prostate Cancer Consensus.

Muscle Invasive Bladder Cancer: 2018 Guidelines

Posted by Michael S. Cookson, MD, MMHC | Jun 2019

Michael S. Cookson, MD, MMHC, outlines the purpose, methodology, and background for recently released guidelines for treating muscle invasive bladder cancer, including cisplatin-based chemotherapy. He highlights recommendation statements regarding patient counseling, neoadjuvant/adjuvant chemotherapy, radical cystectomy, pelvic lymphadenectomies, and more.